Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Group | HBeAg-positive | HBeAg-negative | ||||
Baseline | 168 wk | 192 wk | Baseline | 168 wk | 192 wk | |
A | 7.64 ± 1.01 | 1.18 ± 0.86 | 0.9 ± 0.96 | 6.22 ± 1.25 | 0.62 ± 0.66 | 0.35 ± 0.59 |
B | 7.65 ± 0.95 | 1.13 ± 0.82 | 1.02 ± 0.85 | 6.31 ± 1.37 | 0.36 ± 0.61 | 0.33 ± 0.57 |
P | 0.937 | 0.728 | 0.560 | 0.798 | 0.150 | 0.867 |
Group | HBeAg-positive | HBeAg-negative | ||
168 wk | 192 wk | 168 wk | 192 wk | |
A | 6.44 ± 1.39 | 6.61 ± 1.28 | 5.73 ± 1.25 | 6.05 ± 1.20 |
B | 6.53 ± 1.24 | 6.69 ± 1.12 | 5.99 ± 1.47 | 6.03 ± 1.49 |
P | 0.654 | 0.696 | 0.533 | 0.952 |
Group A (entecavir) | Group B (entecavir maleate) | ||||||
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
Age, yr | 32 | 34 | 28 | 29 | 43 | 34 | 21 |
Sex | Male | Male | Male | Male | Male | Male | Male |
Prior LAM exposure | Yes | Yes | No | No | Yes | Yes | No |
Prior ADV exposure | Yes | Yes | No | No | Yes | No | No |
Baseline | |||||||
HBeAg status | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
HBV DNA, log10 IU/mL | 6.69 | 7.99 | 8.06 | 5.32 | 7.77 | 7.47 | 7.81 |
LAM resistance | No | No | No | No | No | Yes | No |
ADV resistance | Yes | Yes | No | No | Yes | No | No |
At maximum viral suppression | |||||||
wk | 24 | 48 | 72 | 84 | 48 | 12 | 120 |
HBV DNA, log10 IU/mL | 4.07 | 1.18 | 2.97 | 1.76 | 2.26 | 4.78 | TND |
At time of resistance confirmed | |||||||
wk | 144 | 144 | 144 | 144 | 144 | 144 | 144 |
HBV DNA, log10 IU/mL | 6.91 | 6.04 | 4.41 | 1.73 | 6.73 | 4.96 | 1.79 |
Mutational pattern | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M |
rtS202G | rtS202G | rtS202G | rtV173L | rtT184S | rtS202G | rtT184S | |
rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | |
rtM250V | |||||||
Addition of ADV | Yes | Yes | Yes | No | Yes | Yes | No |
HBV DNA, log10 IU/mL | |||||||
Week 168 | 5.14 | 5.08 | 3.18 | 1.84 | 3.43 | 4.86 | TND |
Week 192 | 4.2 | 2.77 | 3.1 | Missing | 2.89 | 4.28 | Missing |
- Citation: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10085